Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 11Lymphoma, Large B-Cell, Diffuse 6Burkitt Lymphoma 4Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma 2Leukemia, Hairy Cell 2Multiple Myeloma 1Multi-centric Castleman's Disease 1Melanoma 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, AIDS-Related 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Lymphoid 1Leukemia, B-Cell 1Leukemia 1Intraocular Lymphoma 1Hematologic Neoplasms 1HIV Infections 1Chromosome 17 deletion 1Bronchiolitis Obliterans Syndrome 1Anemia 1

Interventions

aldesleukin 65Cyclophosphamide 45fludarabine phosphate 30fludarabine 27Interleukin-2 24incomplete Freund's adjuvant 22Ipilimumab 17Specimen Handling 14MART-1 Antigen 14CTLA-4 Antigen 14sargramostim 13Magnetic Resonance Spectroscopy 13Biopsy 13montanide ISA 51 11Nivolumab 11Filgrastim 11Sorafenib 10Interferon-alpha 9trametinib 8pembrolizumab 8dabrafenib 8Sirolimus 7Bevacizumab 7temsirolimus 6Temozolomide 6Taxes 5Paclitaxel 5Introns 5Gene Expression Profiling 5Carboplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Melanoma × ibrutinib × Clear all
NCT02581930 2026-04-30

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
18 enrolled 10 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡